Threshold Pharmaceuticals

Threshold Pharmaceuticals Newswire

Comprehensive Real-Time News Feed for Threshold Pharmaceuticals.

Results 1 - 20 of 89 in Threshold Pharmaceuticals

  1. Threshold Pharmaceuticals Announces Presentations and Webcasts at...Read the original story

    21 hrs ago | Freshnews

    11/25/14 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Barry Selick, Ph.D., Threshold's Chief Executive Officer, will present a company overview at the 26th Annual Piper Jaffray Healthcare Conference on December 2, 2014, at ...

    Comment?

  2. Threshold Pharmaceuticals, Inc. Announces Phase 1/2 Interim Data...Read the original story

    Tuesday Nov 18 | BioSpace

    As reported by the investigator, in a total of 22 evaluable patients, best responses included one complete response and three partial responses for a response rate of 18%, and ten stable disease assessments for a clinical benefit rate of 64%; eight patients had progressive disease. Median progression-free survival was 2.8 months, and median overall survival was 4.6 months.

    Comment?

  3. Threshold Pharmaceuticals announces TH-302, bevacizumab Phase 1/2 interim dataRead the original story

    Monday Nov 17 | Theflyonthewall.com

    Threshold Pharmaceuticals announces TH-302, bevacizumab Phase 1/2 interim data Threshold Pharmaceuticals announced interim data from a U.S. investigator-sponsored Phase 1/2 clinical trial of the investigational anticancer drug TH-302 in combination with bevacizumab for the treatment of glioblastoma, or GBM, the most lethal form of brain cancer. All patients in the study had previously progressed on single-agent bevacizumab, the only FDA-approved therapy for GBM patients with progressive disease following prior therapy.

    Comment?

  4. Relapsed Multiple Myeloma - Pipeline Review, H2 2014 - New Report AvailableRead the original story

    Monday Nov 17 | PR-inside.com

    ... , Curis, Inc., Pharmacyclics, Inc., Array BioPharma Inc., MorphoSys AG, Sevion Therapeutics, Inc., Threshold Pharmaceuticals, Inc., Synta Pharmaceuticals Corp.

    Comment?

  5. Society for NeuroOncology to hold a meetingRead the original story

    Monday Nov 3 | Theflyonthewall.com

    Threshold Pharmaceuticals receives FDA fast track designation for TH-302 Threshold Pharmaceuticals announced that the FDA granted Fast Track designation for TH-302, an investigational anticancer drug, for the treatment of previously untreated patients with metastatic or locally advanced unresectable soft tissue sarcoma, or STS. The FDA established the Fast Track designation process to facilitate the development and expedite the review of drugs intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs.

    Comment?

  6. FDA Fast Tracks Threshold Pharmaceuticals' Anticancer DrugRead the original story

    Wednesday Nov 12 | Pharmaceutical Technology

    Threshold Pharmaceuticals announced on Nov. 11, 2014 that FDA has granted Fast Track designation for TH-302, an investigational anticancer drug, for the treatment of previously untreated patients with metastatic or locally advanced unresectable soft tissue sarcoma . Threshold has designed investigational prodrug TH-302 to be activated in hypoxic regions of solid tumors.

    Comment?

  7. Threshold Pharmaceuticals, Inc. Receives FDA Fast Track Designation...Read the original story

    Tuesday Nov 11 | BioSpace

    Threshold Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration granted Fast Track designation for TH-302, an investigational anticancer drug, for the treatment of previously untreated patients with metastatic or locally advanced unresectable soft tissue sarcoma . The FDA established the Fast Track designation process to facilitate the development and expedite the review of drugs intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs.

    Comment?

  8. Threshold Pharmaceuticals Receives FDA Fast Track Designation for...Read the original story

    Tuesday Nov 11 | Freshnews

    11/11/14 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for TH-302, an investigational anticancer drug, for the treatment of previously untreated ...

    Comment?

  9. SSF's Threshold Pharmaceuticals, Inc. Snags Fast Track Status For Experimental Cancer Drug TH-302Read the original story

    Tuesday Nov 11 | BioSpace

    Threshold Pharmaceuticals Receives FDA Fast Track Designation for TH-302 for the Treatment of Previously Untreated Patients With Metastatic or Locally Advanced Unresectable Soft Tissue Sarcoma SOUTH SAN FRANCISCO, CA-- - Threshold Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration granted Fast Track designation for TH-302, an investigational anticancer drug, for the treatment of previously untreated patients with metastatic or locally advanced unresectable soft tissue sarcoma .

    Comment?

  10. Threshold Pharmaceuticals Announces Presentation and Webcast at the...Read the original story

    Monday Nov 10 | Sys-Con Media

    11/10/14 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Barry Selick, Ph.D., Threshold's Chief Executive Officer, will present a company overview at the Stifel 2014 Healthcare Conference on November, 18, 2014, at 10:20 a.m. ...

    Comment?

  11. Threshold Pharmaceuticals Announces New Phase 1/2 Data on TH-302 in...Read the original story w/Photo

    Thursday Nov 6 | Market Wire

    ... KGaA, Darmstadt, Germany, which includes an option for Threshold to co-commercialize in the U.S. Threshold Pharmaceuticals, Inc. is a biotechnology company focused on the discovery and development of drugs targeting tumor hypoxia, the low oxygen ...

    Comment?

  12. Threshold Pharmaceuticals, Inc. Reports Third Quarter 2014 Financial And Operational ResultsRead the original story

    Tuesday Nov 4 | BioSpace

    Threshold Pharmaceuticals, Inc. , today reported financial results for the third quarter 2014. Revenue for the third quarter ended September 30, 2014 was $3.7 million.

    Comment?

  13. Threshold Pharmaceuticals, Inc.' Partner Merck KGaA, Darmstadt,...Read the original story

    Tuesday Nov 4 | BioSpace

    Threshold Pharmaceuticals, Inc. , today announced that Threshold's partner Merck KGaA, Darmstadt, Germany, through its biopharmaceutical division, has completed target enrollment of 660 patients in the global Phase 3 MAESTRO study assessing the efficacy and safety of TH-302 in combination with gemcitabine in patients with previously untreated, locally advanced unresectable or metastatic pancreatic adenocarcinoma.

    Comment?

  14. Threshold Pharmaceuticals Announces New Phase 1/2 Data on TH-302 in Glioblastoma to be ...Read the original story

    Monday Nov 3 | GuruFocus.com

    Threshold Pharmaceuticals, Inc. today announced that new data from an investigator-sponsored Phase 1/2 trial evaluating the combination of TH-302 and AvastinA in patients with bevacizumab-refractory recurrent glioblastoma will be presented in two posters at the 19th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology held in Miami, Florida, from November 13-16, 2014. The poster titled, "Phase 1/2 study of TH-302, investigational hypoxia-activated prodrug, and bevacizumab in patients with bevacizumab-refractory recurrent glioblastoma" is being presented from 7:30 PM - 9:30 PM Eastern Time on Friday, November 14, 2014.

    Comment?

  15. Threshold Pharmaceuticals Reports Third Quarter 2014 Financial and Operational ResultsRead the original story

    Monday Nov 3 | Freshnews

    11/03/14 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD), today reported financial results for the third quarter 2014. Revenue for the third quarter ended September 30, 2014 was $3.7 million. The operating loss for the third quarter ended September ...

    Comment?

  16. Threshold Pharmaceuticals' Partner Merck KGaA, Darmstadt, Germany,...Read the original story

    Monday Nov 3 | Freshnews

    Threshold Pharmaceuticals, Inc. , today announced that Threshold's partner Merck KGaA, Darmstadt, Germany, through its biopharmaceutical division, has completed target enrollment of 660 patients in the global Phase 3 MAESTRO study assessing the efficacy and safety of TH-302 in combination with gemcitabine in patients with previously untreated, locally advanced unresectable or metastatic pancreatic adenocarcinoma.

    Comment?

  17. Insider Buying: Nipun Davar Acquires 3,000 Shares of Threshold Pharmaceuticals StockRead the original story

    Oct 14, 2014 | AmericanBankingNews.com

    Threshold Pharmaceuticals VP Nipun Davar bought 3,000 shares of the stock on the open market in a transaction dated Monday, October 13th. The shares were purchased at an average price of $2.99 per share, with a total value of $8,970.00.

    Comment?

  18. CTRC-led study lands major FDA grantRead the original story w/Photo

    Oct 6, 2014 | Business Journal

    ... companies. Glioblastoma, while devastating, is not common and so is considered an orphan disease. Threshold Pharmaceuticals, the company that developed the drug, is supplying it for the clinical trial. The Dana-Farber Cancer Institute and the ...

    Comment?

  19. Threshold Pharmaceuticals, Inc. (THLD) - Financial and Strategic SWOT ...Read the original story

    Oct 6, 2014 | PR-inside.com

    2014-10-06 11:16:29 - New Pharmaceuticals market report from GlobalData: "Threshold Pharmaceuticals, Inc. (THLD) - Financial and Strategic SWOT Analysis Review" This comprehensive SWOT profile of Threshold Pharmaceuticals, Inc. provides you an ...

    Comment?

  20. CTRC researcher receives special $1.62 million orphan disease grant from FDARead the original story w/Photo

    Oct 5, 2014 | Medical News

    ... companies. Glioblastoma, while devastating, is not common and so is considered an orphan disease. Threshold Pharmaceuticals, the company that developed the drug, is supplying it for the clinical trial. Also participating in the study will be ...

    Comment?